Выбор редакции

NeoStem falls, author questions AMR-001 after study results

  • NeoStem (NBS -11.1%) started the day in positive territory but quickly faded into the red and is now down double-digits.
  • It looks likely that an article by SA contributor Probio Invest is weighing on the shares.
  • Probio says a study that showed autologous stem cells did not boost heart function "clearly does not bode well for NBS' AMR-001."
3 comments!
НОВОСТИ ПО ТЕМЕ